Vascular Risk Score and Associations With Past, Current, or Future Migraine in Women: Cohort Study.

Autor:	Ibrahimi K; From the Division of Vascular Medicine and Pharmacology (K.I., A.M.B.), Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands; Division of Preventive Medicine (P.M.R., J.E.B.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Epidemiology (P.M.R., J.E.B., T.K.), Harvard T.H. Chan School of Public Health, Boston, MA; PLoegh Lab (C.C.), Program in Cellular and Molecular Medicine (PCMM), Boston Children Hospital and Harvard Medical School, MA; Center for Stroke Research (J.L.R.), Charité-Universitätsmedizin Berlin, Germany; and Institute of Public Health (J.L.R., T.K.), Charité-Universitätsmedizin Berlin, Germany., Rist PM; From the Division of Vascular Medicine and Pharmacology (K.I., A.M.B.), Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands; Division of Preventive Medicine (P.M.R., J.E.B.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Epidemiology (P.M.R., J.E.B., T.K.), Harvard T.H. Chan School of Public Health, Boston, MA; PLoegh Lab (C.C.), Program in Cellular and Molecular Medicine (PCMM), Boston Children Hospital and Harvard Medical School, MA; Center for Stroke Research (J.L.R.), Charité-Universitätsmedizin Berlin, Germany; and Institute of Public Health (J.L.R., T.K.), Charité-Universitätsmedizin Berlin, Germany., Carpenet C; From the Division of Vascular Medicine and Pharmacology (K.I., A.M.B.), Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands; Division of Preventive Medicine (P.M.R., J.E.B.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Epidemiology (P.M.R., J.E.B., T.K.), Harvard T.H. Chan School of Public Health, Boston, MA; PLoegh Lab (C.C.), Program in Cellular and Molecular Medicine (PCMM), Boston Children Hospital and Harvard Medical School, MA; Center for Stroke Research (J.L.R.), Charité-Universitätsmedizin Berlin, Germany; and Institute of Public Health (J.L.R., T.K.), Charité-Universitätsmedizin Berlin, Germany., Rohmann JL; From the Division of Vascular Medicine and Pharmacology (K.I., A.M.B.), Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands; Division of Preventive Medicine (P.M.R., J.E.B.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Epidemiology (P.M.R., J.E.B., T.K.), Harvard T.H. Chan School of Public Health, Boston, MA; PLoegh Lab (C.C.), Program in Cellular and Molecular Medicine (PCMM), Boston Children Hospital and Harvard Medical School, MA; Center for Stroke Research (J.L.R.), Charité-Universitätsmedizin Berlin, Germany; and Institute of Public Health (J.L.R., T.K.), Charité-Universitätsmedizin Berlin, Germany., Buring JE; From the Division of Vascular Medicine and Pharmacology (K.I., A.M.B.), Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands; Division of Preventive Medicine (P.M.R., J.E.B.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Epidemiology (P.M.R., J.E.B., T.K.), Harvard T.H. Chan School of Public Health, Boston, MA; PLoegh Lab (C.C.), Program in Cellular and Molecular Medicine (PCMM), Boston Children Hospital and Harvard Medical School, MA; Center for Stroke Research (J.L.R.), Charité-Universitätsmedizin Berlin, Germany; and Institute of Public Health (J.L.R., T.K.), Charité-Universitätsmedizin Berlin, Germany., Maassen van den Brink A; From the Division of Vascular Medicine and Pharmacology (K.I., A.M.B.), Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands; Division of Preventive Medicine (P.M.R., J.E.B.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Epidemiology (P.M.R., J.E.B., T.K.), Harvard T.H. Chan School of Public Health, Boston, MA; PLoegh Lab (C.C.), Program in Cellular and Molecular Medicine (PCMM), Boston Children Hospital and Harvard Medical School, MA; Center for Stroke Research (J.L.R.), Charité-Universitätsmedizin Berlin, Germany; and Institute of Public Health (J.L.R., T.K.), Charité-Universitätsmedizin Berlin, Germany., Kurth T; From the Division of Vascular Medicine and Pharmacology (K.I., A.M.B.), Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands; Division of Preventive Medicine (P.M.R., J.E.B.), Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Department of Epidemiology (P.M.R., J.E.B., T.K.), Harvard T.H. Chan School of Public Health, Boston, MA; PLoegh Lab (C.C.), Program in Cellular and Molecular Medicine (PCMM), Boston Children Hospital and Harvard Medical School, MA; Center for Stroke Research (J.L.R.), Charité-Universitätsmedizin Berlin, Germany; and Institute of Public Health (J.L.R., T.K.), Charité-Universitätsmedizin Berlin, Germany. tobias.kurth@charite.de.
Jazyk:	angličtina
Zdroj:	Neurology [Neurology] 2022 Oct 17; Vol. 99 (16), pp. e1694-e1701. Date of Electronic Publication: 2022 Oct 17.
DOI:	10.1212/WNL.0000000000201009
Abstrakt:	Background and Objectives: Migraine has consistently been associated with an increased risk of cardiovascular disease (CVD) events. It remains, however, unclear to what extent cardiovascular risk profiles might be linked with migraine activity status and how these profiles relate to the development of migraine. Methods: We used data from a cohort study of female health professionals (Women's Health Study, n = 27,539, age ≥45 years at baseline) without a history of CVD or other major diseases and who provided a blood sample at baseline. Framingham risk scores (FRSs) estimating the 10-year risk of coronary heart disease calculated at baseline were used to create vascular risk categories. The presence or development of self-reported migraine was assessed by questionnaires. Women were classified as having no migraine, history of migraine (experienced migraine in the past but did not experience any migraine attacks in the year before enrollment), active migraine at baseline (active), or incident migraine (first report of migraine during follow-up but not at baseline). We used multinomial logistic regression models to calculate ORs for the association between FRS categories and migraine status. Results: Of the 27,539 participants, a total of 21,927 women did not report migraine, 1,500 women reported a history of migraine, 3,579 had migraine at baseline, and 533 reported migraine for the first time during follow-up. The odds of the probability of having a history of migraine at baseline (vs never migraine) was 76% higher among those with FRS ≥10% compared with FRS ≤1% after adjustment (OR = 1.76, 95% CI 1.39-2.23). In contrast, having FRS ≥10% was associated with reduced odds of having active migraine at baseline (OR = 0.64, 95% CI 0.52-0.80) and with newly reported migraine during follow-up (OR = 0.42, 95% CI 0.22-0.81) when compared with women with FRS category ≤1% and those not reporting migraine. A similar association pattern was observed for FRS categories 5%-9% and 2%-4%. Discussion: High FRS categories were only observed among women with a history of migraine but not with active migraine at baseline or incident migraine after baseline. Our results suggest that the life course of migraine should be considered when studying associations with the vascular system. Our data further suggest that a relatively healthy vascular system, as assessed by the FRS, is associated with active migraine status or developing migraine in the future. (© 2022 American Academy of Neurology.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu